



PRESS RELEASE

Avior Completes a Convertible Debt Financing with Pacific Premier Trust

March 8, 2021

CARY, NC - Avior Bio is pleased to announce the successful completion of a convertible debt financing from Pacific Premier Trust to support expansion of our planned AV104 clinical program in the treatment of chronic liver disease associated pruritus. The transaction was completed on February 22, 2021. The debt note converts upon Avior's Series A financing and has a maturity date of June 22, 2022.

With these funds, Avior plans to complete two single-dose clinical pharmacokinetic studies: a dose proportionality study in normal volunteers; and a study in subjects with mild to moderate chronic liver disease. Completion of these studies will enable us to finalize the design of our Phase 2 program in the treatment of chronic liver disease associated pruritus.

For additional information, please contact Dr. Niraj Vasisht at nvasisht@aviorbio.com. Please visit our website at www.aviorbio.com.